BackBio-Rad Laboratories Overview
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

Bio-Rad Laboratories Debt to Equity

Bio-Rad Laboratories (BIO) has a debt-to-equity ratio of 0.18, below the Healthcare sector average of 0.27.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

0.18

Debt to Equity

0.18

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

Bio-Rad Laboratories (BIO) FAQ

As of the most recent data, BIO shows a debt-to-equity ratio of 0.18. That is below the Healthcare sector average of 0.27. Scroll down for historical charts and peer comparison views.

The Healthcare sector average debt-to-equity ratio is about 0.27. Bio-Rad Laboratories is at 0.18, which is lower that average. That is roughly 32.9% below the sector mean. Use the comparison chart on this page to see how BIO stacks up against individual peers as well.

Investors watch BIO's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Bio-Rad Laboratories's latest reading is 0.18. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this debt-to-equity ratio page, Stockcircle has Bio-Rad Laboratories's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently 0.18) with ownership activity and broader fundamentals.

The Healthcare average debt-to-equity ratio is about 0.27, while BIO is at 0.18. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.